Alnylam Pharmaceuticals, Inc. (ALNY)
USD 237.92
(-3.51%)
USD 237.92
(-3.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.82 Billion | 1.03 Billion | 844.28 Million | 492.85 Million | 219.75 Million | 74.9 Million |
| Cost of Revenue | 310.4 Million | 168.81 Million | 140.14 Million | 78.05 Million | 25.06 Million | 1.8 Million |
| Gross Profit | 1.51 Billion | 868.6 Million | 704.14 Million | 414.8 Million | 194.68 Million | 73.1 Million |
| Operating Expenses | 1.8 Billion | 1.65 Billion | 1.41 Billion | 1.24 Billion | 1.13 Billion | 887.77 Million |
| Selling, General and Administrative Expenses | 795.64 Million | 770.65 Million | 620.63 Million | 588.42 Million | 479 Million | 382.35 Million |
| Research and Development Expenses | 1 Billion | 883.01 Million | 792.15 Million | 654.81 Million | 655.11 Million | 505.42 Million |
| Other Expenses | - | -109.36 Million | -2.05 Million | 45.52 Million | 20.73 Million | 4.17 Million |
| Cost and Expenses | 2.11 Billion | 1.82 Billion | 1.55 Billion | 1.32 Billion | 1.15 Billion | 889.58 Million |
| Operating Income | -282.17 Million | -785.07 Million | -708.65 Million | -828.43 Million | -939.43 Million | -814.67 Million |
| Interest Expense | 121.22 Million | 155.96 Million | 143.02 Million | 84.49 Million | - | 29.26 Million |
| Income Tax Expense | 6.72 Million | 4.16 Million | 680 Thousand | 2.68 Million | 863 Thousand | 823 Thousand |
| Earnings before Tax | -433.51 Million | -1.12 Billion | -852.14 Million | -855.6 Million | -885.25 Million | -760.67 Million |
| Net Income | -440.24 Million | -1.13 Billion | -852.82 Million | -858.28 Million | -886.11 Million | -761.49 Million |
| Earnings Per Share Basic | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 |
| Earnings Per Share Diluted | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 |
| Weighted Average Shares Outstanding | 124.9 Million | 121.68 Million | 118.45 Million | 114.98 Million | 109.26 Million | 100.59 Million |
| Weighted Average Shares Outstanding (Diluted) | 124.9 Million | 121.68 Million | 118.45 Million | 114.98 Million | 109.26 Million | 100.59 Million |
| Gross Margin | 0.83 | 0.84 | 0.83 | 0.84 | 0.89 | 0.98 |
| EBIT Margin | -0.14 | -0.86 | -0.84 | -1.56 | -4.27 | -11.15 |
| Profit Margin | -0.24 | -1.09 | -1.01 | -1.74 | -4.03 | -10.17 |
| EBITDA | -258.24 Million | -926.55 Million | -661.55 Million | -736.33 Million | -868.07 Million | -754.23 Million |
| Earnings Before Tax Margin | -0.15 | -0.76 | -0.84 | -1.68 | -4.27 | -10.88 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 420.14 Million | 659.82 Million | 494.33 Million | 1.82 Billion | 439.71 Million | 750.53 Million |
| Cost of Revenue | 3.92 Million | 68.67 Million | 65.97 Million | 310.4 Million | 85.85 Million | 84.3 Million |
| Gross Profit | 416.22 Million | 591.15 Million | 428.35 Million | 1.51 Billion | 353.86 Million | 666.22 Million |
| Operating Expenses | 573.89 Million | 542.53 Million | 471.79 Million | 1.8 Billion | 470.26 Million | 452.35 Million |
| Selling, General and Administrative Expenses | 220.99 Million | 248.39 Million | 210.79 Million | - | 198.12 Million | 199.17 Million |
| Research and Development Expenses | 270.92 Million | 294.14 Million | 260.99 Million | - | 272.14 Million | 253.17 Million |
| Other Expenses | 81.98 Million | 1.3 Million | -6.03 Million | -17.74 Million | 1.98 Million | -57.65 Million |
| Cost and Expenses | 577.82 Million | 611.21 Million | 537.76 Million | 2.11 Billion | 556.12 Million | 536.66 Million |
| Operating Income | -76.9 Million | 48.61 Million | -43.43 Million | -282.17 Million | -116.4 Million | 213.86 Million |
| Interest Expense | -34.37 Million | 33.25 Million | 35.25 Million | 121.22 Million | 31.33 Million | 30.89 Million |
| Income Tax Expense | -2.9 Million | 5.72 Million | 2.34 Million | 6.72 Million | 183 Thousand | 2.98 Million |
| Earnings before Tax | -108.66 Million | -11.16 Million | -63.58 Million | -433.51 Million | -137.68 Million | 150.74 Million |
| Net Income | -111.57 Million | -16.88 Million | -65.93 Million | -440.24 Million | -137.87 Million | 147.75 Million |
| Earnings Per Share Basic | -0.87 | -0.13 | -0.52 | - | -1.10 | 1.18 |
| Earnings Per Share Diluted | -0.87 | -0.13 | -0.52 | - | -1.10 | 1.15 |
| Weighted Average Shares Outstanding | 128.59 Million | 126.73 Million | 126.13 Million | 124.9 Million | 125.61 Million | 125.22 Million |
| Weighted Average Shares Outstanding (Diluted) | 128.59 Million | 126.73 Million | 126.13 Million | 124.9 Million | 125.61 Million | 131.33 Million |
| Gross Margin | 0.99 | 0.90 | 0.87 | 0.83 | 0.80 | 0.89 |
| EBIT Margin | -0.18 | 0.10 | -0.06 | - | -0.23 | 0.24 |
| Profit Margin | -0.27 | -0.03 | -0.13 | -0.24 | -0.31 | 0.20 |
| EBITDA | -76.9 Million | 63.61 Million | -29.91 Million | - | -102.92 Million | 181.63 Million |
| Earnings Before Tax Margin | -0.18 | 0.07 | -0.09 | -0.15 | -0.26 | 0.28 |
ESR
603118
PBM
6740
03473K
GIPCL